(i) This is a combined synopsis/solicitation for commercial items prepared in accordance with the format in Subpart 12.6 as supplemented with additional information included in this notice. This announcement constitutes the only solicitation; proposals are being requested and a written solicitation will not be issued.

(ii) The solicitation number is 75N95025Q00036 and the solicitation is issued as a request for quotation (RFQ).

This acquisition is for a commercial item or service and is conducted under the authority of the Federal Acquisition Regulation (FAR) Part 13—Simplified Acquisition Procedures;  and FAR Part 12—Acquisition of Commercial Items, and is not expected to exceed the simplified acquisition threshold.

(iii) The solicitation document and incorporated provisions and clauses are those in effect through Federal Acquisition Circular (FAC) Number 2025-01, with effective date 11/12/2024.

(iv) The associated NAICS code is 334516 and the small business size standard is 1,000 Employees. This requirement is full and open with no set-aside restrictions.

(v) This requirement is for the following Promega brand name or equal items:

Qty (30) - Item# N261X(40,000 units) - RNasin Plus RNase Inhibitor

Salient characteristics:

Ribonuclease Inhibitor must be capable of inhibiting RNase A, B and C as well as human placental RNase.

Ribonuclease Inhibitor must be compatible with use in RNA extractions, RT-PCR, cDNA synthesis, microarrays and in vitro transcription/translation.

Ribonuclease Inhibitor must be compatible with Moloney Murine Leukemia Virus Reverse Transcriptase, or ImProm-II Reverse Transcriptases, Taq and Tfl DNA Polymerases.

Ribonuclease Inhibitor must be compatible with quantitative real-time RT-PCR in a TaqMan Assay.

Ribonuclease Inhibitor must be stable against oxidation and heat for up to 15 minutes at 70 °C.

Ribonuclease Inhibitor must be suitable for long-term storage of samples.

Ribonuclease Inhibitor must be commercially available in 1mL aliquots at a concentration of 40ku.
 

(vi) The Government anticipates award of a firm fixed-price purchase order for this acquisition, and the anticipated delivery date is within thirty (30) days after receipt of order (ARO). Delivery will be f.o.b. destination. The place of delivery and acceptance will be 9000 Rockville Pike, Bethesda, MD 20892.

(vii) The provision at FAR 52.252-1, Solicitation Provisions Incorporated by Reference (Feb 1998), applies to this acquisition. This solicitation incorporates one or more solicitation provisions by reference, with the same force and effect as if they were given in full text. Upon request, the Contracting Officer will make their full text available. The offeror is cautioned that the listed provisions may include blocks that must be completed by the offeror and submitted with its quotation or offer. In lieu of submitting the full text of those provisions, the offeror may identify the provision by paragraph identifier and provide the appropriate information with its quotation or offer. Also, the full text of a solicitation provision may be accessed electronically at these addresses:  https://www.acquisition.gov/browse/index/far   https://www.hhs.gov/grants/contracts/contract-policies-regulations/hhsar/index.html   
(End of provision)

The following provisions apply to this acquisition and are incorporated by reference:

• FAR 52.204-7, System for Award Management (Nov 2024)
• FAR 52.204-16, Commercial and Government Entity Code Reporting (Aug 2020)
• FAR 52.204-29, Federal Acquisition Supply Chain Security Act Orders – Representation and Disclosures (Dec 2023)
• FAR 52.211-6, Brand Name or Equal (Aug 1999)
• FAR 52.212-1, Instructions to Offerors-Commercial Products and Commercial Services (Sep 2023)
• FAR 52.212-3, Offeror Representations and Certifications-Commercial Products and Commercial Services (May 2024)
• FAR 52.225-2, Buy American Certificate (Oct 2022)
• HHSAR 352.239-73, Electronic and Information Technology Accessibility Notice (December 18, 2015)

The clause at FAR 52.252-2, Clauses Incorporated by Reference (Feb 1998), applies to this acquisition. This contract incorporates one or more clauses by reference, with the same force and effect as if they were given in full text. Upon request, the Contracting Officer will make their full text available. Also, the full text of a clause may be accessed electronically at these addresses:

https://www.acquisition.gov/browse/index/far     https://www.hhs.gov/grants/contracts/contract-policies-regulations/hhsar/index.html  

(End of clause)

Th